[1. T. I. Oprea and J. Mestres, Drug repurposing: Far beyond new targets for old drugs, AAPS J.14 (2012) 759–763.10.1208/s12248-012-9390-1]Search in Google Scholar
[2. T. T. Ashburn and K. B. Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov.3 (2004) 673–683; https://doi.org/10.1038/nrd146810.1038/nrd146815286734]Search in Google Scholar
[3. V. R. Solomon and H. Lee, Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies, Eur. J. Pharmacol.625 (2009) 220–233; https://doi.org/10.1016/j.ejphar.2009.06.06310.1016/j.ejphar.2009.06.06319836374]Search in Google Scholar
[4. R. Duffy, C. Wade and R. Chang, Discovery of anticancer drugs from antimalarial natural products: a MEDLINE literature review, Drug Discov. Today17 (2012) 942–953.; https://doi.org/10.1016/j.drudis.2012.03.01310.1016/j.drudis.2012.03.01322504324]Search in Google Scholar
[5. T. Kimura, Y. Takabatake, A. Takahashi and Y. Isaka, Chloroquine in cancer therapy: A double-edged sword of autophagy, Cancer Res.73 (2013) 3–7; https://doi.org/10.1158/0008-547210.1158/0008-5472.CAN-12-2464]Search in Google Scholar
[6. R. H. van Huijsduijnen, R. Kiplin Guy, K. Chibale, R. K. Haynes, I. Peitz, G. Kelter, M. A. Phillips, J. L. Vennerstrom, Y. Yuthavong and T. N. C. Wells, Anticancer properties of distinct antimalarial drug classes, PLoS One8 (2013) e82962.10.1371/journal.pone.0082962387700724391728]Search in Google Scholar
[7. A. K. Abdel-Aziz, S. Shouman, E. El-Demerdash, M. Elgendy and A. B. Abdel-Naim, Chloroquine as a promising adjuvant chemotherapy together with sunitinib, Sci. Proc.1 (2014) Article ID e384; https://doi.org/10.14800/sp.38410.14800/sp.384]Search in Google Scholar
[8. F. Liu, Y. Shang and S.-Z. Chen, Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro, Acta Pharmacol. Sin. 35 (2014) 645–652; https://doi.org/10.1038/aps.2014.310.1038/aps.2014.3481403824727941]Search in Google Scholar
[9. A. R. Choi, J. H. Kim, Y. H. Woo, H. S. Kim and S. Yoon, Anti-malarial drugs primaquine and chloroquine have different sensitization effects with anti-mitotic drugs in resistant cancer cells, Anticancer Res. 36 (2016) 1641–1648.10.21873/anticanres.11171]Search in Google Scholar
[10. A. Ganguli, D. Choudhury, S. Datta, S. Bhattacharya and G. Chakrabarti, Inhibition of autophagy by chloroquine potentiates synergistically anti-cancer property of artemisinin by promoting ROS dependent apoptosis, Biochimie107 (2014) 338–349; https://doi.org/10.1016/j.biochi.2014.10.00110.1016/j.biochi.2014.10.00125308836]Search in Google Scholar
[11. C. Verbaanderd, H. Maes, M. B. Schaaf, V. P. Sukhatme, P. Pantziarka, V. Sukhatme, P. Agostinis and G. Bouche, Repurposing drugs in oncology (ReDO) – chloroquine and hydroxychloroquine as anti-cancer agents, eCancer11 (2017) Article ID 781; https://doi.org/10.3332/ecancer.2017.78110.3332/ecancer.2017.781571803029225688]Search in Google Scholar
[12. F. Wang, J. Tang, P. Li, S. Si, H. Yu, X. Yang, J. Tao, Q. Lv, M. Gu, H. Yang and Z. Wang, Chloroquine enhances the radiosensitivity of bladder cancer cells by inhibiting autophagy and activating apoptosis, Cell. Physiol. Biochem.45 (2018) 54–66; https://doi.org/10.1159/00048622210.1159/00048622229316551]Search in Google Scholar
[13. L. Liu, C. Han, H. Yu, W. Zhu, H. Cui, L. Zheng, C. Zhang and L. Yue, Chloroquine inhibits cell growth in human A549 lung cancer cells by blocking autophagy and inducing mitochondrial-mediated apoptosis, Oncol. Rep.39 (2018) 2807–2816.]Search in Google Scholar
[14. A. Kamal A. Aziz, S. Shouman, E. El-Demerdash, M. Elgendy and A. B. Abdel-Naim, Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries, Chem. Biol. Interact.217 (2014) 28–40; https://doi.org/10.1016/j.cbi.2014.04.00710.1016/j.cbi.2014.04.00724751611]Search in Google Scholar
[15. G. W. Soo, J. H. Law, E. Kan, S. Y. Tan, W. Y. Lim, G. Chay, N. I. Bukhari and I. Segarra, Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice, Anticancer Drugs21 (2010) 695–703.10.1097/CAD.0b013e32833c93b3]Search in Google Scholar
[16. Y. K. Wong, C. Xu, K. A. Kalesh, Y. He, Q. Lin, W. S. F. Wong, H. M. Shen and J. Wang, Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action, Med. Res. Rev.37 (2017) 1492–1517.10.1002/med.21446]Search in Google Scholar
[17. https://clinicaltrials.gov/ct2/home (last access May 26, 2019)]Search in Google Scholar
[18. https://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines (last access May 27, 2019)]Search in Google Scholar
[19. N. Vale, R. Moreira and P. Gomes, Primaquine revisited six decades after its discovery, Eur. J. Med. Chem.44 (2009) 937–953; https://doi.org/10.1016/j.ejmech.2008.08.01110.1016/j.ejmech.2008.08.01118930565]Search in Google Scholar
[20. P. M. Njaria, J. Okombo, N. M. Njuguna and K. Chibale, Chloroquine-containing compounds: a patent review (2010 – 2014), Expert Opin. Therap. Patents25 (2015) 1003–1024; https://doi.org/10.1517/13543776.2015.105079110.1517/13543776.2015.1050791710371026013494]Search in Google Scholar
[21. S-J. Yeo, D-X. Liu, H-S. Kim and H. Park, Anti-malarial effect of novel chloroquine derivatives as agents for the treatment of malaria, Malaria J.16 (2017) 80; https://doi.org/10.1186/s12936-017-1725-z10.1186/s12936-017-1725-z531621328212631]Search in Google Scholar
[22. M. A. Avery, D. J. Weldon and K. M. Muraleedharan, Advances in the Discovery of New Antimalarials, in Comprehensive Medicinal Chemistry II (Eds. J. B. Taylor and D. J. Triggle), Vol. 7, Elsevier Ltd., 2007, pp. 765–814; https://doi.org/10.1016/B0-08-045044-X/00227-310.1016/B0-08-045044-X/00227-3]Search in Google Scholar
[23. K. Pavić, Z. Rajić, Z. Mlinarić, L. Uzelac, M. Kralj and B. Zorc, Chloroquine urea derivatives: synthesis and antitumor activity in vitro, Acta Pharm. 68 (2018) 471–483.10.2478/acph-2018-0039]Search in Google Scholar
[24. M. Beus, L. Persoons, D. Schols, L. Uzelac, M. Kralj, Z. Rajić and B. Zorc, Cytotoxicity studies of primaquine and chloroquine fumardiamides, 6th Croatian Congress on Pharmacy with International Participation, Book of Abstract, PO-16, Dubrovnik, April 4–6, 2019]Search in Google Scholar
[25. M. Beus, D. Fontinha, J. Held, Z. Rajić, M. Prudêncio and B. Zorc, Synthesis and antiplasmodial evaluation of novel mefloquine-based fumardiamides, Acta Pharm. 69 (2019) 233–248; https://doi.org/10.2478/acph-2019-001910.2478/acph-2019-001931259728]Search in Google Scholar
[26. G. Džimbeg, B. Zorc, M. Kralj, K. Ester, K. Pavelić, J. Balzarini, E. De Clercq and M. Mintas, The novel primaquine derivatives of N-alkyl, cycloalkyl or aryl urea: synthesis, cytostatic and antiviral activity evaluations, Eur. J. Med. Chem.43 (2008) 1180–1187; https://doi.org/10.1016/j.ejmech.2007.09.00110.1016/j.ejmech.2007.09.00117961851]Search in Google Scholar
[27. M. Šimunović, I. Perković, B. Zorc, K. Ester, M. Kralj, D. Hadjipavlou-Litina and E. Pontiki, Urea and carbamate derivatives of primaquine: synthesis, cytostatic and antioxidant activities, Bioorg. Med. Chem.17 (2009) 5605–5613; https://doi.org/10.1016/j.bmc.2009.06.03010.1016/j.bmc.2009.06.03019581098]Search in Google Scholar
[28. I. Perković, S. Tršinar, J. Žanetić, M. Kralj, I. Martin-Kleiner, J. Balzarini, D. Hadjipavlou-Litina and A. M. Katsori, Novel 1-acyl-4-substituted semicarbazide derivatives of primaquine – synthesis, cytostatic, antiviral and antioxidative studies, J. Enzyme Inhib. Med. Chem.28 (2013) 601–610; https://doi.org/10.3109/14756366.2012.66336610.3109/14756366.2012.66336622380782]Search in Google Scholar
[29. K. Pavić, I. Perković, M. Cindrić, M. Pranjić, I. Martin-Kleiner, M. Kralj, D. Schols, D. Hadjipavlou-Litina, A.-M. Katsori and B. Zorc, Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity, Eur. J. Med. Chem.86 (2014) 502–514; https://doi.org/10.1016/j.ejmech.2014.09.01310.1016/j.ejmech.2014.09.01325203780]Search in Google Scholar
[30. I. Perković, M. Antunović, I. Marijanović, K. Pavić, K. Ester, M. Kralj, J. Vlainić, I. Kosalec, D. Schols, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Novel urea and bis-urea primaquine derivatives with hydroxyphenyl and halogenphenyl substituents: synthesis and biological evaluation, Eur. J. Med. Chem.124 (2016) 622–636; https://doi.org/10.1016/j.ejmech.2016.08.02110.1016/j.ejmech.2016.08.02127614409]Search in Google Scholar
[31. K. Pavić, I. Perković, P. Gilja, F. Kozlina, K. Ester, M. Kralj, D. Schols, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Design, synthesis and biological evaluation of novel primaquine-cinnamic acid conjugates of amide and acylsemicarbazide type, Molecules21 (2016) 1629–1653; https://doi.org/10.3390/molecules2112162910.3390/molecules21121629627368727916811]Search in Google Scholar
[32. K. Pavić, I. Perković, Š. Pospíšilová, M. Machado, D. Fontinha, M. Prudêncio, J. Jampilek, A. Coffey, L. Endersen, H. Rimac and B. Zorc, Primaquine hybrids as promising antimycobacterial and antimalarial agents, Eur. J. Med. Chem.143 (2018) 769–779; https://doi.org/10.1016/j.ejmech.2017.11.08310.1016/j.ejmech.2017.11.08329220797]Search in Google Scholar
[33. J. Vlainić, I. Kosalec, K. Pavić, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Insights into biological activity of ureidoamides with primaquine and amino acid moieties, J. Enzyme Inhib. Med. Chem.33 (2018) 376–382; https://doi.org/10.1080/14756366.2017.142306710.1080/14756366.2017.1423067602103529363364]Search in Google Scholar
[34. J. Levatić, K. Pavić, I. Perković, L. Uzelac, K. Ester, M. Kralj, M. Kaiser, M. Rottmann, F. Supek and B. Zorc, Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity, Eur. J. Med. Chem.146 (2018) 651–667; https://doi.org/10.1016/j.ejmech.2018.01.06210.1016/j.ejmech.2018.01.06229407988]Search in Google Scholar
[35. M. Beus, Z. Rajić, D. Maysinger, Z. Mlinarić, M. Antunović, I. Marijanović, D. Fontinha, M. Prudêncio, J. Held, S. Olgen and B. Zorc, SAHAquines, novel hybrids based on SAHA and primaquine motifs, as potential anticancer and antiplasmodial agents, ChemistryOpen7 (2018) 624–638; https://doi.org/10.1002/open.20180011710.1002/open.201800117610443330151334]Search in Google Scholar
[36. Z. Rajić, M. Beus, H. Michnova, J. Vlainić, L. Persoons, I. Kosalec, J. Jampilek, D. Schols, T. Keser and B. Zorc, Asymmetric primaquine and halogenaniline fumardiamides as novel biologically active Michael acceptors, Molecules23 (2018) 1724; https://doi.org/10.3390/molecules2307172410.3390/molecules23071724610058230011922]Search in Google Scholar
[37. I. Zhang, M. Beus, U. Stochaj, P. U. Le, B. Zorc, Z. Rajić, K. Petrecca and D. Maysinger, Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule, Cell Death Discov. 5 (2019) 41; https://doi.org/10.1038/s41420-018-0103-010.1038/s41420-018-0103-0615828830302275]Search in Google Scholar
[38. K. Pavić, Z. Rajić, H. Michnová, J. Jampílek, I. Perković and B. Zorc, Second generation of primaquine ureas and bis-ureas as potential antimycobacterial agents, Mol. Diver. (2018); https://doi.org/10.1007/s11030-018-9899-z10.1007/s11030-018-9899-z30523579]Search in Google Scholar
[39. M. E. Flanagan, J. A. Abramite, D. P. Anderson, A. Aulabaugh, U. P. Dahal, A. M. Gilbert, C. Li, J. Montgomery, S. R. Oppenheimer, T. Ryder, B. P. Schuff, D. P. Uccello, G. S. Walker, Y. Wu, M. F. Brown, J. M. Chen, M. M. Hayward, M. C. Noe, R. S. Obach, L. Philippe, V. Shanmugasundaram, M. J. Shapiro, J. Starr, J. Stroh and Y. Che, Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors, J. Med. Chem.57 (2014) 10072–10079; https://doi.org/10.1021/jm501412a10.1021/jm501412a25375838]Search in Google Scholar
[40. I. Fernandes, N. Vale, V. de Freitas, R. Moreira, N. Mateus and P. Gomes, Anti-tumoral activity of imidazoquines, a new class of antimalarials derived from primaquine, Bioorg. Med. Chem. Lett.19 (2009) 6914–6917; https://doi.org/10.1016/j.bmcl.2009.10.08110.1016/j.bmcl.2009.10.08119896373]Search in Google Scholar
[41. T. Rossi, A. Coppi, E. Bruni, A. Ruberto, S. Santachiara and G. A. Baggio, Effects of anti-malarial drugs on MCF-7 and Vero cell replication, Anticancer Res. 27 (2007) 2555–2559.]Search in Google Scholar
[42. A. R. Martirosyan, R. Rahim-Bata, A. B. Freeman, C. D. Clarke, R. L. Howard and J. S. Strobl, Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model, Biochem. Pharmacol. 68 (2004) 1729–1738.10.1016/j.bcp.2004.05.00315450938]Search in Google Scholar